Cantor Fitzgerald L. P. Acquires New Position in DiaMedica Therapeutics, Inc. $DMAC

Cantor Fitzgerald L. P. acquired a new position in DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $687,000. Cantor Fitzgerald L. P. owned 0.19% of DiaMedica Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Royal Bank of Canada grew its stake in shares of DiaMedica Therapeutics by 46,879.1% in the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock valued at $588,000 after buying an additional 154,701 shares in the last quarter. Goldman Sachs Group Inc. grew its position in DiaMedica Therapeutics by 76.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 121,802 shares of the company’s stock valued at $462,000 after acquiring an additional 52,854 shares in the last quarter. Jane Street Group LLC lifted its position in shares of DiaMedica Therapeutics by 138.5% during the first quarter. Jane Street Group LLC now owns 100,669 shares of the company’s stock worth $382,000 after purchasing an additional 58,457 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of DiaMedica Therapeutics by 99.6% in the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after purchasing an additional 314,407 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in DiaMedica Therapeutics during the 2nd quarter worth approximately $29,000. Institutional investors and hedge funds own 10.12% of the company’s stock.

DiaMedica Therapeutics Trading Down 0.6%

NASDAQ:DMAC opened at $7.12 on Thursday. DiaMedica Therapeutics, Inc. has a 12-month low of $3.19 and a 12-month high of $10.42. The stock’s 50 day simple moving average is $8.08 and its 200-day simple moving average is $7.61. The firm has a market cap of $370.81 million, a P/E ratio of -10.03 and a beta of 1.09.

Analyst Upgrades and Downgrades

DMAC has been the subject of several analyst reports. Lake Street Capital reiterated a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DiaMedica Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $12.33.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.